Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.45 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5403291 | 0.91 | — | — | |
| SCHEMBL20612872 | 0.88 | ACE2 (0.64) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL9001608 | 0.88 | ACE2 (0.64) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL5977939 | 0.88 | ACE2 (0.64) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL31073666 | 0.88 | ACE2 (0.64) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL28565415 | 0.85 | ACE2 (0.61) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL28565414 | 0.85 | ACE2 (0.61) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL16330413 | 0.85 | BLM (0.65) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL7179523 | 0.85 | BLM (0.65) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL28206746 | 0.83 | BLM (0.62) | ACE2BLMLTA4HGABRR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010629-B2 | Compositions and methods for in vivo imaging | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-03 | — | — | US | disclosed |
| US-20150343094-A1 | COMPOSITIONS AND METHODS FOR IN VIVO IMAGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-12-03 | — | — | US | disclosed |
| WO-2011146390-A2 | COMPOSITIONS AND METHODS FOR IN VIVO IMAGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150343094-A1 | COMPOSITIONS AND METHODS FOR IN VIVO IMAGING | PLIN3, SGMS1, SGMS2 | ACE2 3360/4885BLM 675/4885FOLH1 556/4885 |
| US-10010629-B2 | Compositions and methods for in vivo imaging | PLIN3, SGMS1, SGMS2 | ACE2 3360/4885BLM 675/4885FOLH1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.